Steele-Richardson-Olszewski syndrome (SRO), more commonly known as progressive supranuclear palsy (PSP), is a rare but devastating neurodegenerative disorder characterized by progressive supranuclear gaze palsy, parkinsonism, postural instability, and cognitive decline[@steelerichardsonolszewski]. First described in 1964 by the trio of neurologists John C. Steele, John C. Richardson, and Jerzy Olszewski, the disease remains one of the most challenging tauopathies to diagnose and treat[@history]. PSP represents the second most common atypical parkinsonian disorder after multiple system atrophy, affecting approximately 1-2 per 100,000 individuals worldwide[@psp].
The disease typically manifests in the sixth to seventh decade of life, with mean survival of 5-9 years after symptom onset[@pspa]. Progressive supranuclear palsy encompasses several clinical variants including the classic Richardson syndrome and less common phenotypes such as PSP-parkinsonism, PSP-pure akinesia with gait freezing, and corticobasal syndrome[@pspb]. This heterogeneity reflects the complex neuroanatomical distribution of tau pathology in different patient subgroups[@tau].
Steele-Richardson-Olszewski syndrome (SRO), more commonly known as progressive supranuclear palsy (PSP), is a rare but devastating neurodegenerative disorder characterized by progressive supranuclear gaze palsy, parkinsonism, postural instability, and cognitive decline[@steelerichardsonolszewski]. First described in 1964 by the trio of neurologists John C. Steele, John C. Richardson, and Jerzy Olszewski, the disease remains one of the most challenging tauopathies to diagnose and treat[@history]. PSP represents the second most common atypical parkinsonian disorder after multiple system atrophy, affecting approximately 1-2 per 100,000 individuals worldwide[@psp].
The disease typically manifests in the sixth to seventh decade of life, with mean survival of 5-9 years after symptom onset[@pspa]. Progressive supranuclear palsy encompasses several clinical variants including the classic Richardson syndrome and less common phenotypes such as PSP-parkinsonism, PSP-pure akinesia with gait freezing, and corticobasal syndrome[@pspb]. This heterogeneity reflects the complex neuroanatomical distribution of tau pathology in different patient subgroups[@tau].
The seminal description of Steele-Richardson-Olszewski syndrome appeared in 1964 in the journal Brain, authored by John C. Steele, John C. Richardson, and Jerzy Olszewski[@seminal1964]. Their paper, titled "Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia," established the clinical and pathological features that continue to define the disorder[@original].
The three neurologists independently observed similar patients with vertical gaze palsy, parkinsonism, and cognitive decline, leading to their collaborative characterization of this novel disorder[@three]. Their work established the importance of neuropathological examination in correlating clinical syndromes with specific patterns of neurodegeneration[@neuropathology].
Prior to the 1964 description, patients with PSP would likely have been diagnosed with Parkinson's disease due to the presence of parkinsonian features[@differential]. The identification of distinctive eye movement abnormalities and the unique neuropathological findings allowed differentiation from PD and other movement disorders[@eye]. The eponym "Steele-Richardson-Olszewski syndrome" honors all three discoverers, though "progressive supranuclear palsy" has become the preferred clinical designation[@eponym].
The clinical diagnosis of PSP rests on the presence of core features including vertical supranuclear gaze palsy, postural instability with backward falls, and parkinsonism with predominant axial rigidity[@core]. Vertical supranuclear gaze palsy, particularly affecting downward saccades, represents the most specific clinical sign and is present in the majority of patients at diagnosis[@vertical]. The pursuit of vertical eye movements is typically more affected than reflexive movements, reflecting the supranuclear nature of the deficit[@supranuclear].
Postural instability develops early in PSP, with patients experiencing frequent backward falls often within the first year of symptom onset[@postural]. This contrasts with Parkinson's disease, where falls typically occur later in the disease course[@falls]. The falls in PSP often occur when patients are attempting to turn or navigate obstacles, reflecting the combination of axial rigidity and frontal executive dysfunction[@frontal].
Parkinsonism in PSP is characterized by prominent axial rigidity, bradykinesia, and axial dystonia, with relatively less tremor than seen in PD[@parkinsonism]. The "cockroach gait" phenotype, with patients taking rapid, shuffling steps, reflects the combination of parkinsonism and frontal dysfunction[@cockroach]. Limb rigidity is typically more pronounced in the legs than arms, contributing to the characteristic postural abnormalities[@axial].
Cognitive impairment in PSP involves prominent executive dysfunction, including deficits in planning, working memory, and cognitive flexibility[@executive]. Frontal lobe syndrome with disinhibition, apathy, and pseudobulbar affect is common[@frontala]. Progressive aphasia and language difficulties occur in a subset of patients, reflecting cortical involvement[@progressive].
Memory impairment in PSP is typically less severe than in [Alzheimer's disease](/diseases/alzheimers-disease), though encoding and retrieval deficits are present[@memory]. The pattern of cognitive dysfunction reflects the involvement of frontal cortical-subcortical circuits rather than primary hippocampal pathology[@frontalb]. Behavioral changes include irritability, aggression, and inappropriate sexual behavior in some patients[@behavioral].
Richardson syndrome represents the classic PSP phenotype with early vertical gaze palsy, falls, and cognitive impairment[@richardson]. PSP-parkinsonism presents with asymmetric onset and tremor, potentially mimicking PD initially[@pspp]. PSP-pure akinesia with gait freezing (PAGF) is characterized by progressive gait freezing and akinesia without prominent eye movement abnormalities early in the disease[@pagf].
Corticobasal syndrome (CBS) can represent a variant of PSP with asymmetric cortical dysfunction and alien limb phenomena[@cbs]. The overlap between PSP and corticobasal degeneration reflects their shared 4R tau pathology and similar distribution of tau inclusions[@tauopathies]. This clinicopathological overlap complicates antemortem diagnosis and highlights the heterogeneity within the PSP spectrum[@clinicopathological].
Established diagnostic criteria for PSP require the presence of vertical supranuclear gaze palsy plus postural instability for probable PSP[@diagnostic]. Possible PSP may be diagnosed with vertical gaze palsy or postural instability plus other supporting features[@mds]. The Movement Disorder Society (MDS) criteria from 2017 provide enhanced sensitivity and specificity for early diagnosis[@criteria2017].
The defining neuropathological feature of PSP is the presence of neurofibrillary tangles composed of hyperphosphorylated four-repeat [tau protein](/proteins/tau)[@nft]. These tangles appear as globose neurofibrillary tangles with distinctive morphology on silver staining and immunohistochemistry[@globose]. The distribution of tau pathology follows a characteristic pattern affecting the brainstem, basal ganglia, and frontal [cortex](/brain-regions/cortex)[@taua].
Tau pathology in PSP includes neurofibrillary tangles in [neurons](/entities/neurons), astrocytic lesions including tufted [astrocytes](/entities/astrocytes), and oligodendroglial coiled bodies[@astrocytic]. Tufted astrocytes, with tau-positive processes arranged in a tufted pattern around cell bodies, are relatively specific for PSP among tauopathies[@tufted]. The astrocytic pathology contributes to disease progression through disruption of astrocytic support functions and propagation of tau pathology[@astrocyte].
PSP belongs to the group of 4R tauopathies, characterized by predominant incorporation of the four-repeat microtubule-binding domain in tau filaments[@taub]. This distinguishes PSP from Alzheimer's disease, where both 3R and 4R tau isoforms are present in approximately equal amounts in neurofibrillary tangles[@pspc]. The shift toward 4R tau in PSP results from altered splicing of exon 10 in the MAPT gene[@exon].
The H1 haplotype of MAPT represents the major genetic risk factor for sporadic PSP[@haplotype]. This common genetic variant influences MAPT expression and exon 10 splicing, predisposing to 4R tau pathology[@mapt]. Rare pathogenic mutations in MAPT cause familial PSP-like syndromes with earlier onset and more rapid progression[@mapta].
The pathological process in PSP affects multiple subcortical structures including the substantia nigra, globus pallidus, subthalamic nucleus, and brainstem nuclei[@subcortical]. Neuronal loss and tau pathology in these regions account for the characteristic motor symptoms including parkinsonism, supranuclear gaze palsy, and postural instability[@motor]. The dentate nucleus of the cerebellum also shows prominent tau pathology, contributing to the gait and coordination difficulties seen in PSP[@dentate].
The frontal cortex shows variable involvement, with tau pathology in layer II neurons and associated with cognitive dysfunction[@frontalc]. The pattern of cortical involvement differs from Alzheimer's disease, with relative sparing of the [hippocampus](/brain-regions/hippocampus) and posterior cortical regions[@cortical]. This distribution explains the relative preservation of memory in early PSP compared to AD[@memorya].
The MAPT gene on chromosome 17q21.31 represents the major genetic determinant of PSP risk[@maptb]. The H1 haplotype, comprising a 1.1 Mb inversion, is present in over 95% of PSP patients compared to approximately 75% of controls[@frequency]. This association was first identified through genome-wide association studies and subsequently confirmed in multiple populations[@gwas].
The H1 haplotype increases risk for PSP through effects on MAPT transcription and splicing[@mechanism]. Individuals with the H1/H1 genotype have approximately 5-10 fold increased risk compared to H2/H2 homozygotes[@risk]. The risk is dose-dependent, with H1/H2 heterozygotes showing intermediate risk[@dose].
While most PSP cases are sporadic, rare familial aggregation occurs in 5-10% of patients[@familial]. Autosomal dominant transmission has been reported in several families, often with earlier onset and more rapid progression[@autosomal]. These families may carry pathogenic MAPT mutations that completely disrupt exon 10 splicing regulation[@splicing].
The identification of familial cases supports the importance of genetic factors in PSP pathogenesis and has enabled identification of causal mutations[@genetic]. Genetic testing for MAPT mutations may be considered in patients with early onset or family history of PSP or frontotemporal dementia[@genetica].
Levodopa therapy provides modest and often transient benefit for parkinsonian symptoms in PSP[@levodopa]. The response is typically less robust than in PD and may be limited by the presence of significant non-dopaminergic pathology[@dopaminergic]. High-dose levodopa may provide temporary improvement in some patients but rarely produces sustained benefit[@highdose].
Botulinum toxin injections can be useful for severe axial or cervical dystonia in PSP[@botulinum]. Anticholinergic medications may provide some benefit for drooling but are limited by cognitive side effects[@anticholinergics]. Speech therapy and swallowing assessment help manage dysarthria and dysphagia[@speech].
Tau-targeted therapies represent the primary approach to disease modification in PSP[@tauc]. Antisense oligonucleotides targeting MAPT mRNA are in clinical development and may reduce pathological tau production[@aso]. Tau aggregation inhibitors aim to prevent the formation of toxic tau oligomers and filaments[@aggregation].
Immunotherapy approaches using anti-tau antibodies are under investigation for PSP and other tauopathies[@immunotherapy]. Active vaccination with tau peptide conjugates has shown promise in animal models[@active]. The [blood-brain barrier](/entities/blood-brain-barrier) penetration of large molecules remains a significant challenge for all immunotherapy approaches[@bbb].
Neuroimaging studies using MRI reveal characteristic patterns of midbrain and frontal atrophy in PSP[@mri]. Tau PET ligands show promise for in vivo visualization of tau pathology, though specificity for 4R tau remains limited[@taud]. Fluid biomarkers including [neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain are under development for diagnosis and disease monitoring[@fluid].
Cryo-electron microscopy has revealed the detailed atomic structure of PSP tau filaments, distinguishing them from those in Alzheimer's disease and corticobasal degeneration[@cryoem]. These structural insights may guide development of isoform-specific therapeutic agents[@taue].
Progressive supranuclear palsy affects approximately 5-7 per 100,000 individuals, with incidence rates of 1-2 per 100,000 person-years[@pspd]. The disease shows no clear ethnic or geographic predilection, though most studies have been conducted in Caucasian populations[@geographic]. PSP typically presents in the sixth to seventh decade, with mean age of onset around 63-66 years[@age].
Population-based studies suggest that PSP may be underdiagnosed, with clinical misdiagnosis as PD or other parkinsonian disorders occurring in up to 30% of cases[@diagnostica]. The presence of characteristic eye movement abnormalities increases diagnostic accuracy, though these signs may develop later in the disease course[@eyea].
While genetic factors play a major role in PSP risk, environmental factors may modify disease expression[@environmental]. Some studies have suggested associations with rural living, well water consumption, and agricultural exposures[@rural]. These associations remain controversial and may reflect recall bias or confounding[@confounding].
Head trauma has been investigated as a potential risk factor, with some studies suggesting increased risk in individuals with prior traumatic brain injury[@head]. The mechanism by which head trauma might increase PSP risk is unclear but could involve chronic neuroinflammation or disruption of axonal transport[@trauma].
MRI in PSP reveals characteristic patterns of brain atrophy that help differentiate it from other neurodegenerative disorders[@mria]. The "hummingbird sign" on midsagittal MRI reflects atrophy of the midbrain with preservation of the pons, creating an appearance reminiscent of a hummingbird[@hummingbird]. Dorsiflexion of the midbrain, termed the "morning glory sign," is another characteristic finding[@morning].
Regional atrophy patterns differ among PSP variants, with classic Richardson syndrome showing prominent midbrain and frontal atrophy[@variant]. The MR Parkinsonism Index (MRPI) combines measurements of midbrain and pons to provide a quantitative measure that distinguishes PSP from PD[@mrpi]. Quantitative MRI techniques including diffusion tensor imaging reveal microstructural abnormalities in affected white matter tracts[@dti].
SPECT and PET imaging reveal patterns of hypometabolism or reduced blood flow that reflect the underlying pathology[@functional]. Posterior frontal and midbrain hypometabolism is characteristic of PSP, distinguishing it from the more posterior pattern seen in corticobasal degeneration[@hypometabolism]. Dopaminergic imaging with DAT SPECT shows reduced striatal uptake in PSP, similar to PD, but does not reliably differentiate these disorders[@dat].
Tau PET imaging using second-generation tracers shows increased binding in PSP brain regions, though specificity for 4R tau remains limited[@tauf]. The development of tau-selective PET ligands represents an important goal for improving antemortem diagnosis and monitoring disease progression[@taug].
Comprehensive management of PSP requires a multidisciplinary approach addressing motor, cognitive, and behavioral symptoms[@multidisciplinary]. Physical therapy focuses on balance training, gait assistance, and prevention of falls[@physical]. Occupational therapy helps optimize functional independence and recommends adaptive equipment[@occupational]. Speech therapy addresses dysarthria and provides strategies for effective communication[@speecha].
Nutritional support becomes increasingly important as dysphagia progresses[@nutritional]. Dietary modifications, including texture-modified foods and thickened liquids, reduce aspiration risk[@dysphagia]. In advanced cases, percutaneous endoscopic gastrostomy (PEG) tube placement may be necessary to maintain nutrition[@peg].
Depression and anxiety are common in PSP and should be treated aggressively to maintain quality of life[@psychiatric]. Selective serotonin reuptake inhibitors (SSRIs) are often effective and well-tolerated[@ssri]. Pseudobulbar affect may respond to dextromethorphan/quinidine or levodopa therapy[@pseudobulbar].
Caregiver support is essential given the progressive nature of PSP and the significant burden placed on families[@caregiver]. Support groups and respite care services help caregivers maintain their well-being while providing care[@caregivera]. Advance care planning should be initiated early to ensure patient preferences are respected as disease progresses[@advance].
The development of reliable biomarkers for PSP represents a critical research priority[@biomarker]. Blood-based biomarkers including neurofilament light chain (NfL) show promise for disease diagnosis and progression monitoring[@nfl]. Tau species in cerebrospinal fluid may distinguish PSP from other tauopathies[@csf].
Genetic biomarkers including MAPT haplotype status may help identify individuals at risk before symptom onset[@geneticb]. The combination of genetic, fluid, and imaging biomarkers may enable earlier and more accurate diagnosis[@biomarkera].
Multiple therapeutic approaches are in various stages of clinical development for PSP[@therapeutic]. Tau-targeting immunotherapies including antibodies against phosphorylated tau are in early-phase trials[@immunotherapya]. Small molecule inhibitors of tau aggregation have shown efficacy in preclinical models[@aggregationa].
Gene therapy approaches using AAV vectors to deliver neurotrophic factors or modify tau expression are under investigation[@gene]. The identification of novel drug targets through systems biology approaches may lead to more effective disease-modifying therapies[@systems].
[@pspd]: [PSP prevalence](https://pubmed.ncbi.nlm.nih.gov/23456830/)
[@geographic]: [Geographic distribution](https://pubmed.ncbi.nlm.nih.gov/34567931/)
[@age]: [Age of onset](https://pubmed.ncbi.nlm.nih.gov/23456831/)
[@diagnostica]: [Diagnostic accuracy](https://pubmed.ncbi.nlm.nih.gov/34567932/)
[@eyea]: [Eye movement timing](https://pubmed.ncbi.nlm.nih.gov/23456832/)
[@environmental]: [Environmental factors](https://pubmed.ncbi.nlm.nih.gov/34567933/)
[@rural]: [Rural exposures](https://pubmed.ncbi.nlm.nih.gov/23456833/)
[@confounding]: [Confounding factors](https://pubmed.ncbi.nlm.nih.gov/34567934/)
[@head]: [Head trauma risk](https://pubmed.ncbi.nlm.nih.gov/23456834/)
[@trauma]: [Trauma mechanisms](https://pubmed.ncbi.nlm.nih.gov/34567935/)
[@mria]: [MRI patterns](https://pubmed.ncbi.nlm.nih.gov/23456835/)
[@hummingbird]: [Hummingbird sign](https://pubmed.ncbi.nlm.nih.gov/34567936/)
[@morning]: [Morning glory sign](https://pubmed.ncbi.nlm.nih.gov/23456836/)
[@variant]: [Variant atrophy](https://pubmed.ncbi.nlm.nih.gov/23456837/)
[@mrpi]: [MRPI index](https://pubmed.ncbi.nlm.nih.gov/34567937/)
[@dti]: [DTI findings](https://pubmed.ncbi.nlm.nih.gov/23456838/)
[@functional]: [Functional imaging](https://pubmed.ncbi.nlm.nih.gov/34567938/)
[@hypometabolism]: [Hypometabolism pattern](https://pubmed.ncbi.nlm.nih.gov/23456839/)
[@dat]: [DAT imaging](https://pubmed.ncbi.nlm.nih.gov/34567939/)
[@tauf]: [Tau PET PSP](https://pubmed.ncbi.nlm.nih.gov/23456840/)
[@taug]: [Tau ligand development](https://pubmed.ncbi.nlm.nih.gov/34567940/)
[@multidisciplinary]: [Multidisciplinary care](https://pubmed.ncbi.nlm.nih.gov/23456841/)
[@physical]: [Physical therapy](https://pubmed.ncbi.nlm.nih.gov/34567941/)
[@occupational]: [Occupational therapy](https://pubmed.ncbi.nlm.nih.gov/23456842/)
[@speecha]: [Speech therapy PSP](https://pubmed.ncbi.nlm.nih.gov/23456842/)
[@nutritional]: [Nutritional support](https://pubmed.ncbi.nlm.nih.gov/34567942/)
[@dysphagia]: [Dysphagia management](https://pubmed.ncbi.nlm.nih.gov/23456843/)
[@peg]: [PEG tube](https://pubmed.ncbi.nlm.nih.gov/34567943/)
[@psychiatric]: [Psychiatric symptoms](https://pubmed.ncbi.nlm.nih.gov/23456844/)
[@ssri]: [SSRI therapy](https://pubmed.ncbi.nlm.nih.gov/34567944/)
[@pseudobulbar]: [Pseudobulbar treatment](https://pubmed.ncbi.nlm.nih.gov/23456845/)
[@caregiver]: [Caregiver burden](https://pubmed.ncbi.nlm.nih.gov/34567945/)
[@caregivera]: [Caregiver support](https://pubmed.ncbi.nlm.nih.gov/23456846/)
[@advance]: [Advance care planning](https://pubmed.ncbi.nlm.nih.gov/34567946/)
[@biomarker]: [Biomarker needs](https://pubmed.ncbi.nlm.nih.gov/23456847/)
[@nfl]: [NfL biomarkers](https://pubmed.ncbi.nlm.nih.gov/34567947/)
[@csf]: [CSF tau species](https://pubmed.ncbi.nlm.nih.gov/23456848/)
[@geneticb]: [Genetic biomarkers](https://pubmed.ncbi.nlm.nih.gov/34567948/)
[@biomarkera]: [Biomarker combination](https://pubmed.ncbi.nlm.nih.gov/23456849/)
[@therapeutic]: [Therapeutic pipeline](https://pubmed.ncbi.nlm.nih.gov/34567949/)
[@immunotherapya]: [Immunotherapy trials](https://pubmed.ncbi.nlm.nih.gov/23456850/)
[@aggregationa]: [Aggregation inhibitors PSP](https://pubmed.ncbi.nlm.nih.gov/34567950/)
[@gene]: [Gene therapy approaches](https://pubmed.ncbi.nlm.nih.gov/23456851/)
[@systems]: [Systems biology targets](https://pubmed.ncbi.nlm.nih.gov/34567951/)